Drugs / Coly Mycin M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06198764 | Jul 2023 → Mar 2026 | mental disorder | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coly Mycin M | “Coly Mycin M is the originally marketed colistimethate sodium for injection.” NCT06198764 ↗ |
| Known as | Colistimethate sodium for injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06198764 ↗ |
| Route | Intravenous | “Intravenous infusion of colistimethate sodium for injection for 7-14 days.” NCT06198764 ↗ |